Hansen Medical and CardioFocus Inc. Co-Host Symposium on Latest Innovations for Atrial Fibrillation at German Cardiac Society

MANNHEIM, GERMANY--(Marketwire - April 09, 2010) - Hansen Medical and CardioFocus will co-host a Lunch Symposium on the Latest Innovative Technologies in the Treatment of Atrial Fibrillation (AF) at the German Cardiac Society Annual Meeting, April 10, 2010.

What: Professor Dr. Werner Jung and Dr. Boris Schmidt will chair the lunch symposium featuring presentations from world-renowned physicians, followed by discussion. Presentations will include:

• The Use of Novel Catheter Contact Technologies in Paroxysmal AF Ablation, by Professor Dr. Josef Kautzner.
• Significant Reduction of Radiation Exposure in AF Ablation, by Professor Dr. Stephan Willems.
• Pulmonary Vein Isolation with the Novel Endoscopic Ablation System, by Professor Dr. Karl-Heinz Kuck.
• Toward Reliable and Persistent Pulmonary Vein Isolation, by Dr. Petr Neuzil.

When: 11.30 - 1pm, Saturday, April 10, Congress Center Rosengarten Mannheim, Level 2,
Room 6.

About Hansen Medical, Inc.
Hansen Medical Inc., based in Mountain View, Calif., develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. Its first product, the Sensei® Robotic Catheter system, is a robotic navigation system that enables clinicians to place mapping catheters in hard-to-reach anatomical locations within the heart easily, accurately and with stability during complex cardiac arrhythmia procedures. The safety and effectiveness of the Sensei system for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei system is cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.

About CardioFocus
CardioFocus was founded in 1999. The company's laser ablation research is shedding new light on therapies for atrial fibrillation. The U.S. Food and Drug Administration (FDA) has not approved the CardioFocus Endoscopic Ablation System for general use. Additional information can be found at www.cardiofocus.com.